Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740919 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 751
- Enrollment target
NCT03740919 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 751 participants.
The verdict
NCT03740919, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 751 participants
- Enrollment target
Study Summary
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Degludec
- DRUG Insulin Lispro
- DRUG LY900014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 751 participants |
| Start Date | 2019-04-07 |
| Est. Completion | 2021-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03740919
The ClinicalTrials.gov registry entry for NCT03740919 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 751 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Insulin Glargine is the first listed.
NCT03740919 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03740919 about?
NCT03740919 is a clinical study titled "A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes". The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
What is the current status of trial NCT03740919?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 751 participants. The study started on 2019-04-07. Estimated completion is 2021-07-02.
What interventions are being tested in trial NCT03740919?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Degludec (DRUG), Insulin Lispro (DRUG), LY900014 (DRUG).
Who is sponsoring clinical trial NCT03740919?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.